Simris Alg AB Class B AI Stock Analysis
Want to see SE:SIMRIS.B full AI Analyst Report?
Simris Alg AB Class B (SIMRIS.B) AI Stock Analysis
Simris Alg AB Class B
(Nasdaq OMX AB:SIMRIS.B)
Extremely weak financial performance with declining revenue, negative margins, and high leverage is the dominant factor. Mildly positive technical indicators offer limited support, while negative P/E and absent dividend further constrain the score.
Simris Alg AB Class B (SIMRIS.B) vs. iShares MSCI Sweden ETF (EWD)
- Market Cap
- SEK 160.46M
- Dividend Yield
- ―
- Average Volume (3M)
- 195.42K
- Price to Earnings (P/E)
- -3.3
- Beta (1Y)
- 0.25
- Revenue Growth
- -50.41%
- EPS Growth
- 56.74%
- Country
- Sweden
- Employees
- 5
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Simris Alg AB Class B Business Overview & Revenue Model
Company Description
Operating both within Sweden and across global markets, Simris Alg AB (publ) specializes in the production and sale of nutritional supplements and food products derived from algae. Its product portfolio includes Simris Algae Omega-3, a unique plant-d...
Simris Alg AB Class B Financial Statement Overview
Summary
TTM revenue fell 26% with negative gross margins, persistent net losses, debt-to-equity above 116, and negative operating cash flow of -15.4M highlight severe financial challenges.
Income Statement
18Very NegativeBalance Sheet
9Very NegativeCash Flow
22Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.39M | 1.61M | 2.89M | 4.35M | 4.08M | 6.14M |
| Gross Profit | -21.63M | -31.34M | 1.22M | 2.01M | -742.00K | -2.07M |
| EBITDA | -15.43M | -17.32M | -19.79M | -22.36M | -18.00M | -24.81M |
| Net Income | -25.63M | -26.81M | -34.60M | -37.30M | -24.42M | -28.36M |
Balance Sheet | ||||||
| Total Assets | 137.73M | 148.38M | 157.06M | 174.55M | 185.71M | 29.20M |
| Cash, Cash Equivalents and Short-Term Investments | 7.99M | 1.47M | 1.95M | 5.67M | 3.99M | 961.00K |
| Total Debt | 89.69M | 87.68M | 2.04M | 2.67M | 2.13M | 3.13M |
| Total Liabilities | 136.97M | 148.85M | 151.42M | 148.94M | 162.68M | 10.98M |
| Stockholders Equity | 767.00K | -470.00K | 5.64M | 25.61M | 23.03M | 18.22M |
Cash Flow | ||||||
| Free Cash Flow | -12.83M | -16.27M | -18.63M | -37.96M | -40.57M | -18.39M |
| Operating Cash Flow | -15.38M | -16.05M | -18.02M | -36.35M | -18.19M | -18.14M |
| Investing Cash Flow | -552.00K | -224.00K | -613.00K | -1.61M | -22.38M | -253.00K |
| Financing Cash Flow | 22.89M | 15.79M | 14.91M | 39.63M | 43.60M | 2.84M |
Simris Alg AB Class B Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SIMRIS.B, the sentiment is Negative. The current price of 0.10 is below the 20-day moving average (MA) of 0.12, below the 50-day MA of 0.11, and below the 200-day MA of 0.10, indicating a bearish trend. The MACD of -0.00 indicates Positive momentum. The RSI at 36.44 is Neutral, neither overbought nor oversold. The STOCH value of 18.91 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:SIMRIS.B.
Simris Alg AB Class B Peers Comparison
Overall Rating
SE:SIMRIS.B46Neutral
SE:BIOEX42Neutral
SE:MAGLE41Neutral
SE:IBT.B39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 46Neutral | SEK 160.46M | -3.35 | 1209.72% | ― | -50.41% | 56.74% | |
| 42Neutral | SEK 113.54M | -5.57 | -116.56% | ― | -37.50% | 1.01% | |
| 41Neutral | SEK 63.60M | -0.03 | -46.30% | ― | 1.80% | -1367.42% | |
| 39Underperform | SEK 961.86M | -11.44 | -89.70% | ― | ― | 19.94% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SE:SIMRIS.B | Simris Alg AB Class B | 0.10 | -0.01 | -12.84% | |
| SE:IBT.B | Infant Bacterial Therapeutics | 69.70 | 17.70 | 34.04% | |
| SE:MAGLE | Magle Chemoswed Holding AB | 0.25 | -20.55 | -98.78% | |
| SE:BIOEX | Bioextrax AB | 2.42 | 0.38 | 18.80% | |
| SE:BIOWKS | Bio-Works Technologies AB | 3.02 | 0.27 | 9.82% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 20, 2026
